Literature DB >> 33349955

The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys.

Rebecca Burch1,2, Paul Rizzoli1,2, Elizabeth Loder2.   

Abstract

BACKGROUND AND OBJECTIVES: Accurate, up-to-date estimates of the burden of migraine and severe headache are important for evidence-based decision-making about workforce needs and the distribution of health resources. We used data from US government health surveys to report the prevalence, trends, and impact of this condition by age, sex, and poverty status.
METHODS: We identified the most recent, publicly available summary statistics from the National Hospital Ambulatory Medical Care Survey, the National Ambulatory Medical Care Survey, and the National Health Interview Survey. We extracted and compiled relevant information from each study, with an emphasis on sex, age, and economic-related statistics.
RESULTS: The age-adjusted prevalence of migraine and severe headache in the United States has remained stable over many years. In 2018, the age-adjusted prevalence was 15.9% across all adults. The sex ratio also remains stable, with 21% of women and 10.7% of men affected. Migraine continues to be an important public health problem, accounting for roughly 4 million emergency department (ED) visits in 2016, when headache was the fifth most common reason for an ED visit overall and the third most common reason for ED visits in females 15-64. Migraine also accounted for over 4.3 million office visits. Many adults with migraine or severe headaches are disadvantaged. In 2018, for example, roughly 40% of US adults with migraine were unemployed, and a similar proportion were classified as poor or "near poor." Roughly one in five had no health insurance and about a third had a high school education or less.
CONCLUSIONS: Migraine and severe headaches are a serious public health issue in the United States, with the highest impact in women of childbearing age and those of lower socioeconomic status. Socioeconomic disadvantages also are highly prevalent among those with headaches. The economic consequences of the current coronavirus pandemic are likely to exacerbate all of these inequities. Increased attention to this high impact chronic pain condition, and improved funding for treatment provision and research, are warranted to reduce the future burden of disease.
© 2020 American Headache Society.

Entities:  

Keywords:  determinants of health; epidemiology; headache; migraine; prevalence; socioeconomic

Year:  2020        PMID: 33349955     DOI: 10.1111/head.14024

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  14 in total

Review 1.  A Comprehensive Review of Celecoxib Oral Solution for the Acute Treatment of Migraine.

Authors:  Nazir Noor; Courtney LaChute; Mathew Root; Jasmine Rogers; Madeleine Richard; Giustino Varrassi; Ivan Urits; Omar Viswanath; Nazih Khater; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-04-26

Review 2.  Neurologic Manifestations of Catastrophic Antiphospholipid Syndrome.

Authors:  Rafid Mustafa
Journal:  Curr Neurol Neurosci Rep       Date:  2022-08-30       Impact factor: 6.030

3.  Headache, eating disorders, PTSD, and comorbidity: implications for assessment and treatment.

Authors:  Timothy D Brewerton; Molly M Perlman; Ismael Gavidia; Giulia Suro; Joel Jahraus
Journal:  Eat Weight Disord       Date:  2022-05-23       Impact factor: 3.008

Review 4.  Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale.

Authors:  Fred Cohen; Hsiangkuo Yuan; Stephen D Silberstein
Journal:  BioDrugs       Date:  2022-04-27       Impact factor: 7.744

Review 5.  New Halogen-Containing Drugs Approved by FDA in 2021: An Overview on Their Syntheses and Pharmaceutical Use.

Authors:  Davide Benedetto Tiz; Luana Bagnoli; Ornelio Rosati; Francesca Marini; Luca Sancineto; Claudio Santi
Journal:  Molecules       Date:  2022-03-02       Impact factor: 4.411

Review 6.  Role of Atogepant in the Treatment of Episodic Migraines: Clinical Perspectives and Considerations.

Authors:  Fred Cohen; Hsiangkuo Yuan
Journal:  Ther Clin Risk Manag       Date:  2022-04-22       Impact factor: 2.755

7.  Gut microbiota and migraine.

Authors:  Joshua Crawford; Sufang Liu; Feng Tao
Journal:  Neurobiol Pain       Date:  2022-04-09

8.  Use of the Sphenopalatine Ganglion Block to Treat Migraine Headaches in the Emergency Department.

Authors:  Aaron Morgan; Gennaro Romanello
Journal:  Cureus       Date:  2022-01-19

Review 9.  New Insights on Metabolic and Genetic Basis of Migraine: Novel Impact on Management and Therapeutical Approach.

Authors:  Irene Simonetta; Renata Riolo; Federica Todaro; Antonino Tuttolomondo
Journal:  Int J Mol Sci       Date:  2022-03-11       Impact factor: 5.923

Review 10.  Clinical Evidence of Cannabinoids in Migraine: A Narrative Review.

Authors:  Flavia Lo Castro; Carlo Baraldi; Lanfranco Pellesi; Simona Guerzoni
Journal:  J Clin Med       Date:  2022-03-08       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.